Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E22.76 EPS (ttm)4.45 Insider Own0.50% Shs Outstand1.51B Perf Week8.48%
Market Cap153.10B Forward P/E10.87 EPS next Y9.32 Insider Trans6.02% Shs Float1.49B Perf Month13.98%
Income7.46B PEG0.92 EPS next Q1.90 Inst Own92.50% Short Float6.62% Perf Quarter24.82%
Sales17.44B P/S8.78 EPS this Y10.40% Inst Trans-2.12% Short Ratio8.53 Perf Half Y22.47%
Book/sh10.50 P/B9.65 EPS next Y16.25% ROA28.60% Target Price111.43 Perf Year76.63%
Cash/sh5.82 P/C17.40 EPS next 5Y24.67% ROE57.70% 52W Range57.31 - 101.65 Perf YTD34.86%
Dividend- P/FCF22.28 EPS past 5Y11.90% ROI18.70% 52W High0.19% Beta0.73
Dividend %- Quick Ratio2.20 Sales past 5Y16.00% Gross Margin81.20% 52W Low77.70% ATR2.05
Employees6100 Current Ratio2.50 Sales Q/Q136.10% Oper. Margin56.20% RSI (14)83.51 Volatility1.98% 1.85%
OptionableYes Debt/Eq0.59 EPS Q/Q378.30% Profit Margin42.80% Rel Volume1.14 Prev Close101.28
ShortableYes LT Debt/Eq0.49 EarningsJul 23 AMC Payout0.00% Avg Volume11.54M Price101.84
Recom1.70 SMA208.81% SMA5015.59% SMA20028.70% Volume5,755,139 Change0.55%
15-Aug-14Initiated FBR Capital Outperform $125
11-Aug-14Reiterated Argus Buy $90 → $110
28-Jul-14Reiterated Maxim Group Buy $112 → $127
24-Jul-14Reiterated RBC Capital Mkts Outperform $96 → $102
28-Apr-14Reiterated Maxim Group Buy $101 → $112
21-Feb-14Reiterated Barclays Overweight $90 → $95
10-Feb-14Reiterated Argus Buy $84 → $90
05-Feb-14Reiterated RBC Capital Mkts Outperform $90 → $96
05-Feb-14Reiterated Needham Buy $85 → $95
05-Feb-14Reiterated Maxim Group Buy $98 → $101
04-Feb-14Upgrade Robert W. Baird Neutral → Outperform $65 → $103
28-Jan-14Reiterated Deutsche Bank Buy $95 → $132
06-Jan-14Reiterated UBS Buy $80 → $102
02-Jan-14Reiterated Maxim Group Buy $89 → $98
20-Dec-13Reiterated RBC Capital Mkts Outperform $80 → $90
01-Nov-13Reiterated Argus Buy $70 → $84
30-Oct-13Reiterated RBC Capital Mkts Outperform $72 → $80
30-Oct-13Reiterated Barclays Overweight $68 → $74
26-Jul-13Reiterated Stifel Buy $65 → $75
26-Jul-13Reiterated RBC Capital Mkts Outperform $62 → $72
20-Aug-14 10:24AM  Gilead Sciences: 'Risk of HCV Price War Overblown,' Bernstein Says at Barrons.com
10:08AM  Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus Zacks
19-Aug-14 08:19PM  Top 3 Sector ETFs' Recent History at Investor's Business Daily
05:19PM  The All-Time New Highs... Yahoo Finance Blogs
04:25PM  Amgen (AMGN) Reports Encouraging Top-Line Data on AMG 416 Zacks
08:42AM  10 S&P 500 companies growing faster than their rivals MarketWatch
08:42AM  10 S&P 500 companies growing faster than their rivals at MarketWatch
07:26AM  Celladon Corp. (CLDN) Jumps: Stock Adds 11.3% in Session Zacks
18-Aug-14 03:45PM  Achillion Pharmaceuticals Soars on Mid-Stage HCV Study Data Zacks
03:35PM  4 Large-Cap Healthcare Stocks To Watch at Investopedia
02:29PM  Should Achillion Pharma (ACHN) Be In Your Portfolio Now? Zacks
01:52PM  Achillion Pharmaceuticals Up On Buyout Rumors at Investor's Business Daily
01:46PM  Jazz, Celgene Lead Top 4 Drugmaker Profit Margins at Investor's Business Daily
12:34PM  Gilead Scores Legal Victory Over Roche for Sovaldi, Shares Up Zacks
12:02PM  3 Big Stocks on Traders' Radars at TheStreet
09:16AM  [video] Cramer: Market about Russia-Ukraine at CNBC
07:12AM  #PreMarket Primer: Monday, August 18: Jackson Hole Draws Market Attention Benzinga
16-Aug-14 08:02AM  Gilead, Vipshop Lead Top 4 IBD 50 Stocks In EPS Gains at Investor's Business Daily
15-Aug-14 06:10PM  Biotech Leader Gilead Sciences Scores Sovaldi Win at Investor's Business Daily
05:44PM  Gilead Wins Sovaldi Dispute With Roche, U.K. Nod at Investor's Business Daily
05:15PM  [video] Stock Pops & Drops: ADSK, MNST, JCP, GILD at CNBC
05:12PM  US STOCKS-Wall St ends mixed, recovers from Ukraine-driven slide Reuters
05:01PM  Markets Close The Week On Negative Note As Ukraine Worries Mount Benzinga
04:49PM  Stocks close mixed on renewed geopolitical concerns at CNBC
04:25PM  Stocks close mixed on renewed geopolitical concerns at CNBC
04:09PM  Stocks close mixed on renewed geopolitical concerns at CNBC
03:18PM  Stocks mixed; geopolitical tensions back in focus at CNBC
12:31PM  [$$] U.K. Drug Panel Backs Sovaldi at The Wall Street Journal
12:30PM  Gilead Sciences: Arbitrator Removes 'Doomsday Scenario' at Barrons.com
12:23PM  Gilead Wins Sovaldi Dispute With Roche, U.K. Nod at Investor's Business Daily
12:03PM  Gilead says panel rejects Roche's claims on hep C drug Reuters
12:02PM  Gilead wins critical Sovaldi legal fight, Roche finds consolation at MarketWatch
10:25AM  Biotech Stock Achillion Is Soaring After Good News About Its Hepatitis C Drug Business Insider
10:25AM  Biotech Stock Achillion Is Soaring After Good News About Its Hepatitis C Drug Business Insider
10:08AM  [$$] Gilead Notches Win in Sovaldi Tussle at The Wall Street Journal
09:44AM  Stocks to Watch: Gilead, Dillard's, Monster Beverage at The Wall Street Journal
09:05AM  Achillion rises on hepatitis C drug study AP
08:31AM  [$$] U.K. Drug Panel Endorses Sovaldi at The Wall Street Journal
08:25AM  [$$] Gilead Notches Win in Sovaldi Tussle at The Wall Street Journal
08:10AM  Gilead says wins favorable ruling on hep C drug Reuters
07:51AM  [$$] Gilead Notches Win in Sovaldi Tussle at The Wall Street Journal
07:19AM  Coverage initiated on Gilead Sciences by FBR Capital Briefing.com
07:17AM  [$$] Gilead Notches Victory in Sovaldi Tussle at The Wall Street Journal
06:00AM  GILEAD SCIENCES INC Files SEC form 8-K, Other Events EDGAR Online
05:23AM  [$$] U.K. Drug Panel Endorses Sovaldi at The Wall Street Journal
14-Aug-14 09:44PM  UK Recommends Covering Sovaldi Hepatitis C Pill at The Wall Street Journal
09:02PM  UK Recommends Covering Sovaldi Hepatitis Pill at The Wall Street Journal
07:02PM  UK watchdog backs £400 a day hepatitis C drug at Financial Times
07:01PM  UK cost body backs pricey Gilead hepatitis pill for some patients Reuters
07:01PM  Gileads Sovaldi Wins Backing of U.K. Health-Cost Regulator at Bloomberg
05:39PM  The New Large Cap All Time Highs... Yahoo Finance Blogs
04:20PM  Amgen's FOCUS Study on Multiple Myeloma Drug Kyprolis Fails Zacks
03:10PM  [video] Red hot biotech stocks at CNBC
06:01AM  Bob Doll doubles down on 2014 picks, adds three more Yahoo Finance
13-Aug-14 04:01PM  Bob Doll doubles down on 2014 picks, adds three more Yahoo Finance
02:42PM  Vertex to end sales of hepatitis C drug Incivek Reuters
02:05PM  Should Gilead Sciences (GILD) Be in Your Portfolio? Zacks
12:50PM  BioDelivery Sciences Q2 Loss Narrows, Up on Solid Revenues Zacks
10:49AM  Pharmacyclics Has Edge Over Blood Cancer Competitors at TheStreet
06:49AM  Celladon (CLDN) Falls: Stock Goes Down 6.2% Zacks
01:00AM  Bull of the Day: Gilead Sciences (GILD) Zacks
12-Aug-14 06:05PM  Biogen, Apple: Top Mutual Fund Bets Big On Best Ideas at Investor's Business Daily
05:23PM  Ebola Drugs Success Bolsters Approach for Other Diseases at Bloomberg
03:20PM  What is Your Stock's Earnings Yield? Zacks
10:48AM  Intercept Pharma Soars On Liver-Disease Drug Data at Investor's Business Daily
10:40AM  From Riches to Rags: Vertex Discontinues Incivek as Sales Evaporate at The Wall Street Journal
10:30AM  Spectrum Pharmaceuticals (SPPI) Posts Strong Earnings in Q2 Zacks
09:38AM  Supernus (SUPN) Posts Strong Earnings in Q2, Guidance Raised Zacks
07:06AM  Five Prime Therapeutics (FPRX) Jumps: Stock Adds 10.3% in Session Zacks
06:41AM  Time to Focus on Gilead Sciences (GILD) for Strong Earnings Growth Potential Zacks
06:00AM  'Mad Money' Lightning Round: I'm Not Crazy About El Pollo Loco at TheStreet
11-Aug-14 06:18PM  Tight Trade After A Breakout Often Morphs Into A Flat Base Investor's Business Daily
04:35PM  How Gilead Sciences Became A Big Name In Biotech at Investopedia
01:12PM  Tech, Health Care Lead Q2 Earnings Beats at Investor's Business Daily
11:08AM  Why Gilead Sciences (GILD) Stock Is Rising Today at TheStreet
08:50AM  Emergent BioSolutions Misses on Earnings, Ups Revenue View Zacks
08:10AM  Achillion Pharmaceuticals Up on Narrower-than-Expected Loss Zacks
07:24AM  The Zacks Analyst Blog Highlights: Natural Gas Services, Sanmina, Green Dot, Gilead Sciences and Verizon Zacks
09-Aug-14 01:04PM  GILEAD SCIENCES INC Financials EDGAR Online Financials
08-Aug-14 04:17PM  Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices at MarketWatch
02:15PM  Gilead offers to sell Hepatitis C drug in India at 99% off U.S. prices at MarketWatch
01:07PM  Market Strategy: Play Energy & IT Zacks
08:50AM  An Update On My Search To Find The Next Warren Buffett at Forbes
08:18AM  Even At $900 (Vs. $84,000 In US) Hep C Cure Sovaldi's Cost Could Be Unacceptable In India at Forbes
07-Aug-14 09:51AM  How Much? Gilead Will Charge $900 for Sovaldi in India at The Wall Street Journal
08:48AM  Zacks Earnings Trends Highlights: Intel, Micron Technology, Apple, Gilead Sciences and Verizon Zacks
07:03AM  #PreMarket Primer: Thursday, August 7: Russia Set To Release A List Of Banned Goods Benzinga
06-Aug-14 01:23PM  Celgene: Five Reasons to Be Bullish at Barrons.com
04-Aug-14 05:57PM  [video] IMX Data Shows Home Gamers Increased Equity Exposure at TheStreet
05:19PM  GILEAD SCIENCES INC Files SEC form 10-Q, Quarterly Report EDGAR Online
03:07PM  What Will the new Hepatitis C Medicines do to Medicare Part D? at The Wall Street Journal
02:59PM  What Will the new Hepatitis C Medicines do to Medicare Part D? at The Wall Street Journal
02:19PM  What Will the new Hepatitis C Medicines do to Medicare Part D? at The Wall Street Journal
01-Aug-14 07:08PM  TAL Education, Team Health Join The IBD 50 Resistance at Investor's Business Daily
03:41PM  Cures for Canines at New York Times
03:41PM  Biotechnology Turns to the Furred and Four-Legged at New York Times
12:35PM  Pharmacyclics Q2 Earnings Get Mixed Reception at Investor's Business Daily
12:01PM  Wall Street Transcript Interview with Charles R. Kummeth, the President and CEO of Bio-Techne (TECH) Wall Street Transcript
08:49AM  Zacks Earnings Trends Highlights: Intel, Micron Technology, Apple and Gilead Sciences Zacks
31-Jul-14 10:09PM  Oregon Medicaid targets expensive hepatitis drug AP
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines for the treatment of life threatening diseases in North America, South America, Europe, and the Asia-Pacific. The company's products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Sovaldi, Viread, and Hepsera products for the treatment of liver disease. It also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in adult patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages for the treatment of HIV, liver, oncology/inflammation, cardiovascular, and respiratory diseases. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Washington Robin LEVP, CFOAug 14Option Exercise40.5633,5561,361,03183,388Aug 18 01:10 PM
Washington Robin LEVP, CFOAug 14Sale95.5633,5563,206,61149,832Aug 18 01:10 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Option Exercise26.9916,728451,48948,713Aug 12 04:25 PM
Carter Paul RutherfordEVP Commercial OpsAug 08Sale91.5816,7281,531,88131,985Aug 12 04:25 PM
MARTIN JOHN CChairman and CEOAug 01Option Exercise8.01140,6251,125,7034,570,012Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Option Exercise26.995,000134,95020,641Aug 05 05:31 PM
Carter Paul RutherfordEVP Commercial OpsAug 01Option Exercise0.002,500033,205Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Option Exercise22.3030,600682,49080,432Aug 05 01:35 PM
MARTIN JOHN CChairman and CEOAug 01Sale91.53140,62512,871,8134,429,387Aug 04 06:16 PM
Whitley Richard JamesDirectorAug 01Sale91.005,000455,00015,641Aug 05 05:31 PM
Washington Robin LEVP, CFOAug 01Sale91.4830,6002,799,34849,832Aug 05 01:35 PM
MOORE NICHOLAS GDirectorJul 28Option Exercise26.6245,0001,197,67545,000Jul 30 12:17 PM
MOORE NICHOLAS GDirectorJul 28Sale90.5645,0004,075,4030Jul 30 12:17 PM
Cogan John FrancisDirectorJul 21Option Exercise14.345,00071,68847,405Jul 23 01:31 PM
Cogan John FrancisDirectorJul 21Sale89.675,000448,34342,405Jul 23 01:31 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Option Exercise26.9916,728451,48947,433Jul 10 01:41 PM
Carter Paul RutherfordEVP Commercial OpsJul 08Sale86.4516,7281,446,07430,705Jul 10 01:41 PM
MARTIN JOHN CChairman and CEOJul 01Option Exercise8.01140,6251,125,7034,570,012Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Option Exercise23.6131,000731,853159,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Option Exercise26.995,000134,95020,641Jul 02 04:24 PM
MARTIN JOHN CChairman and CEOJul 01Sale84.84140,62511,929,9614,429,387Jul 03 02:28 PM
Alton Gregg HEVP, Corp & Med AffairsJul 01Sale84.1233,0002,776,076126,694Jul 03 03:14 PM
Whitley Richard JamesDirectorJul 01Sale83.655,000418,25015,641Jul 02 04:24 PM
Washington Robin LEVP, CFOJun 30Sale83.9810,400873,40346,774Jul 02 01:44 PM
Cogan John FrancisDirectorJun 23Option Exercise14.345,00071,68847,405Jun 25 01:51 PM
Cogan John FrancisDirectorJun 23Sale81.825,000409,12342,405Jun 25 01:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Option Exercise16.4090,0001,475,550209,302Jun 18 04:33 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJun 16Sale80.9090,0007,280,784119,302Jun 18 04:33 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Option Exercise26.9916,728451,48947,433Jun 11 12:59 PM
Carter Paul RutherfordEVP Commercial OpsJun 09Sale79.4316,7281,328,64530,705Jun 11 12:59 PM
Washington Robin LEVP, CFOJun 04Sale82.526,426530,27457,174Jun 05 05:46 PM
Whitley Richard JamesDirectorJun 02Option Exercise26.995,000134,95020,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Option Exercise23.6031,000731,600161,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Option Exercise8.01140,6251,125,7034,570,012Jun 04 02:48 PM
Whitley Richard JamesDirectorJun 02Sale80.955,000404,75015,641Jun 04 05:18 PM
Alton Gregg HEVP, Corp & Med AffairsJun 02Sale81.3533,0002,684,514128,694Jun 04 05:21 PM
MARTIN JOHN CChairman and CEOJun 02Sale81.32140,62511,435,8364,429,387Jun 04 02:48 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Option Exercise16.4090,0001,475,550209,302May 16 02:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMay 14Sale80.6590,0007,258,752119,302May 16 02:52 PM
Carter Paul RutherfordEVP Commercial OpsMay 10Option Exercise0.005,000021,290May 13 02:27 PM
MILLIGAN JOHN FPresident and COOMay 08Option Exercise8.01100,000800,5001,038,048May 09 06:58 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Option Exercise23.3340,000933,132170,694May 12 03:38 PM
Alton Gregg HEVP, Corp & Med AffairsMay 08Sale80.0040,0003,200,000130,694May 12 03:38 PM
Washington Robin LEVP, CFOMay 06Option Exercise24.913,00074,71552,832May 08 07:13 PM
Washington Robin LEVP, CFOMay 06Sale79.913,000239,73049,832May 08 07:13 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Option Exercise21.5811,000237,325143,694May 05 05:23 PM
Whitley Richard JamesDirectorMay 01Option Exercise26.995,000134,95017,778May 05 05:36 PM
MARTIN JOHN CChairman and CEOMay 01Option Exercise8.01140,6251,125,7034,570,012May 05 05:52 PM
Whitley Richard JamesDirectorMay 01Sale78.635,000393,15012,778May 05 05:36 PM
Alton Gregg HEVP, Corp & Med AffairsMay 01Sale79.0813,0001,028,024130,694May 05 05:23 PM
MARTIN JOHN CChairman and CEOMay 01Sale79.02140,62511,112,0344,429,387May 05 05:52 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Option Exercise16.4090,0001,475,550209,302Apr 16 12:34 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOApr 14Sale67.0390,0006,032,482119,302Apr 16 12:34 PM
Cogan John FrancisDirectorApr 08Option Exercise14.345,00071,68844,542Apr 10 02:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Option Exercise24.4316,728408,68945,290Apr 10 03:52 PM
Carter Paul RutherfordEVP Commercial OpsApr 08Sale70.5316,7281,179,78228,562Apr 10 03:52 PM
Cogan John FrancisDirectorApr 08Sale70.555,000352,75539,542Apr 10 02:52 PM
MARTIN JOHN CChairman and CEOApr 01Option Exercise8.01140,6251,125,7034,570,012Apr 03 03:20 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Option Exercise21.5811,000237,325145,694Apr 03 03:20 PM
Whitley Richard JamesDirectorApr 01Option Exercise26.995,000134,95018,116Apr 03 04:00 PM
Whitley Richard JamesDirectorApr 01Sale73.095,000365,45013,116Apr 03 04:00 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale73.2013,000951,640132,694Apr 03 03:20 PM
MARTIN JOHN CChairman and CEOApr 01Sale73.26140,62510,302,0284,429,387Apr 03 03:20 PM
Cogan John FrancisDirectorMar 14Option Exercise14.3414,000200,72553,542Mar 18 12:56 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Option Exercise16.4090,0001,475,550209,302Mar 18 01:36 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOMar 14Sale75.8990,0006,829,705119,302Mar 18 01:36 PM
Cogan John FrancisDirectorMar 14Sale76.4414,0001,070,10139,542Mar 18 12:56 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Option Exercise21.5816,728360,90745,290Mar 12 01:39 PM
Carter Paul RutherfordEVP Commercial OpsMar 10Sale79.3216,7281,326,83328,562Mar 12 01:39 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Option Exercise21.5831,000668,825117,484Mar 05 02:50 PM
MARTIN JOHN CChairman and CEOMar 03Option Exercise8.01140,6251,125,7034,397,860Mar 05 02:51 PM
MARTIN JOHN CChairman and CEOMar 03Sale81.74140,62511,495,3264,257,235Mar 05 02:51 PM
Alton Gregg HEVP, Corp & Med AffairsMar 03Sale81.8433,0002,700,68784,484Mar 05 02:50 PM
Washington Robin LEVP, CFOFeb 28Option Exercise22.3030,600682,49080,432Mar 04 09:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Option Exercise24.0099,0002,375,550114,842Mar 04 02:56 PM
Carter Paul RutherfordEVP Commercial OpsFeb 28Sale83.5599,0008,271,93515,842Mar 04 02:56 PM
Washington Robin LEVP, CFOFeb 28Sale83.6530,6002,559,63549,832Mar 04 09:09 PM
MOORE NICHOLAS GDirectorFeb 26Option Exercise26.6220,000532,30020,000Feb 28 12:50 PM
MOORE NICHOLAS GDirectorFeb 26Sale84.0520,0001,681,0700Feb 28 12:50 PM
Washington Robin LEVP, CFOFeb 21Option Exercise23.605,000118,00054,832Feb 25 03:41 PM
Washington Robin LEVP, CFOFeb 21Sale83.245,000416,21849,832Feb 25 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Option Exercise22.0219,068419,78219,068Feb 21 02:32 PM
Washington Robin LEVP, CFOFeb 19Sale83.3696880,69249,832Feb 21 03:41 PM
MOORE NICHOLAS GDirectorFeb 19Sale83.1219,0681,584,9900Feb 21 02:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Option Exercise14.5090,0001,305,225158,124Feb 19 02:09 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOFeb 14Sale81.3690,0007,322,22268,124Feb 19 02:09 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Option Exercise21.5816,728360,90731,861Feb 12 04:44 PM
Carter Paul RutherfordEVP Commercial OpsFeb 10Sale79.1016,7281,323,19815,133Feb 12 04:44 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 03Option Exercise21.5831,000668,825118,516Feb 05 06:34 PM
MARTIN JOHN CChairman and CEOFeb 03Option Exercise8.01140,6251,125,7034,396,892Feb 05 06:53 PM
MARTIN JOHN CChairman and CEOFeb 03Sale79.96140,62511,244,0894,256,267Feb 05 06:53 PM
Alton Gregg HEVP, Corp & Med AffairsFeb 03Sale80.7833,0002,665,59385,516Feb 05 06:34 PM
YOUNG KEVINEVP, Commercial OperationsJan 23Option Exercise16.40100,0001,639,500316,418Jan 27 08:07 PM
YOUNG KEVINEVP, Commercial OperationsJan 23Sale81.44100,0008,144,150216,418Jan 27 08:07 PM
Alton Gregg HEVP, Corp & Med AffairsJan 21Option Exercise19.94120,0002,392,393152,938Jan 22 07:15 PM
Alton Gregg HEVP, Corp & Med AffairsJan 21Sale80.00120,0009,600,00032,938Jan 22 07:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 14Option Exercise14.5090,0001,305,22590,000Jan 16 02:15 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJan 14Sale74.2390,0006,681,1470Jan 16 02:15 PM
Alton Gregg HEVP, Corp & Med AffairsJan 02Option Exercise19.11111,0002,121,519145,938Jan 06 05:39 PM
MARTIN JOHN CChairman and CEOJan 02Option Exercise8.01140,6251,125,7034,197,746Jan 06 05:38 PM